Dupilumab for children and teens with alopecia areata
Tests dupilumab against placebo in children and teens with moderate to severe alopecia areata.
Key facts
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Where
- Chicago, Irvine, New York, and San Diego, United StatesSee the 5 sites
- Trial code
- Registry title
- Dupilumab in the Treatment of Pediatric Alopecia Areata
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 76 people, planned
- Started
- 11 Jul 2024
- Expected to end
- 30 Apr 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Dupilumab
- Placebo
- Record updated
- 2 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teens with moderate to severe alopecia areata, a condition where the immune system causes patchy hair loss. It tests dupilumab against a placebo (dummy injection).
- Age
- 6 to 17 years
- Sex
- All sexes
- Disease stage
- Moderate to severe alopecia areata for at least 6 months, with 50% or more of the scalp affected (SALT score). Some hair must have grown back within 7 years of the last hair loss episode.
- Earlier treatment
- Cannot have had dupilumab before. No systemic immune-suppressing drugs (such as cyclosporine, steroids, methotrexate, oral JAK inhibitors) or UV light therapy within 4 weeks before the start. No steroid creams, tacrolimus or pimecrolimus on the skin within 1 week before the start.
- Biomarker or test result
- A screening IgE blood level of 200 or more, and/or a personal or family history of allergic conditions (asthma, atopic dermatitis, allergic rhinitis, food allergy or eosinophilic esophagitis).
Main reasons for not taking part
- Pregnant or breastfeeding
- Hair loss from another cause, or cause unknown
- Severe, uncontrolled asthma
- Active infection, weak immune system, or active hepatitis B, hepatitis C or HIV
- Cancer within the last 5 years, or a live vaccine within 28 days before randomization
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Male or female participants who are at least 6 years old and under 18 years old, who can provide assent (if appropriate), and for whom signed informed consent can be provided by parent or legal guardian prior to participation in any study assessments or procedures; -- Participant is able to adhere to the study visit schedule and other protocol requirements
- Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product (IP), FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:; Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR; Option 2: Male or female condom (latex condom or non-latex condom NOT made out of natural [animal] membrane [for example, polyurethane])
- Participant has a history of at least 6 months of moderate to severe AA (≥ 50% scalp involvement) as measured using the SALT score
- Participant has a screening IgE ≥ 200 and/or personal and/or familial history of atopy (including asthma, atopic dermatitis, allergic rhinitis, food allergy, or eosinophilic esophagitis)
- Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing
Who cannot take part
- Participant's cause of hair loss is indeterminable and/or they have concomitant causes of alopecia, such traction, cicatricial, pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia (i.e. Ludwig Type III or Norwood-Hamilton Stage ≥ V)
- Participant has a concurrent or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, intestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease
- Participant has received a live attenuated vaccine ≤ 28 days prior to study randomization
- Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic or intralesional corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, oral JAK inhibitor (tofacitinib, ruxolitinib, baricitinib, ritlecitinib, or investigational oral JAK Inhibitors) or ultraviolet (UV) phototherapy with/without Psoralen Ultraviolet A (PUVA) therapy, within 4 weeks prior to the Week 0/Baseline visit
- Participant has been previously treated with dupilumab
- Participant has used topical corticosteroids, and/or tacrolimus, and/or pimecrolimus within 1 week before the Baseline visit
- Severe, uncontrolled asthma (having 2 or exacerbations in the last 12 months that require systemic steroids and/or hospitalization) or a history of life-threatening asthma exacerbations while on appropriate anti-asthmatic medications
- Participant has an active bacterial, viral, or helminth parasitic infections; OR a history of ongoing, recurrent severe infections requiring systemic antibiotics
- Known active hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or positive HIV serology at the time of screening for subjects determined by the investigators to be at high-risk for this disease
- Participant has a suspected or active lymphoproliferative disorder or malignancy; OR a history of malignancy within 5 years before the Baseline assessment, except for completely treated in situ non-melanoma skin and cervical cancers without evidence of metastasis
- History of adverse systemic or allergic reactions to any component of the study drug
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
- Participant has a history of AA with no evidence of hair regrowth for ≥ 7 years since their last episode of hair loss
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- Participant is pregnant or breastfeeding
- Participant with a known or suspected underlying immunodeficiency or immune-compromised state as determined by the investigator
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Where in United States
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Brian ChengTaking people
- Northwestern University Feinberg School of MedicineChicago, United StatesContact: Brian ChengTaking people
- University of California, IrvineIrvine, United StatesContact: Marcos HurtadoTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesContact: Giselle SingerTaking people
- University of California San DiegoSan Diego, United StatesContact: Luis F MartinezTaking people
About the trial
What the trial wants to find out
This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants completing through Week 48. All subjects must have evidence of hair regrowth within the last 7 years of their last episode of hair loss; and have screening IgE ≥200 and/or have personal and/or familial history of atopy.
Read full original descriptionShow less
Study participation will be up to 124 weeks, consisting of: a screening period of up to 4 weeks; a 48-week placebo-controlled period; a 48-week open-label extension period; followed by a 24-week follow-up period.
The 2 groups in the trial
- DupilumabTreatment being tested
200 mg or 300 mg SC injections every 2 or 4 weeks (weight based)
- PlaceboPlacebo, for comparison
Injections without active ingredients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Dupilumab in the Treatment of Pediatric Alopecia Areata
- Plain-language title
- Dupilumab for children and teens with alopecia areataGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT05866562, who can take part
- Record updated
- 2 September 2026